Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620308 · ClinicalTrials.gov registry record · Phase 1
CD-NP in Subjects With Stable Chronic Heart Failure
A Phase 1 study of Stable Chronic Heart Failure, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00620308: Completed Phase 1 study of Stable Chronic Heart Failure, sponsored by Mayo Clinic.
NCT00620308 is a Phase 1 study of Stable Chronic Heart Failure that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620308, a Phase 1 study of Stable Chronic Heart Failure, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This human physiologic study will evaluate the effects of a new drug called CD-NP in individuals with stable chronic heart failure, with a focus on evaluating responses of the kidneys and the hormonal system.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CD-NP
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT00620308 record still lists
NCT00620308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Stable Chronic Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00620308 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00620308 about?
NCT00620308 is a clinical study titled "CD-NP in Subjects With Stable Chronic Heart Failure". This human physiologic study will evaluate the effects of a new drug called CD-NP in individuals with stable chronic heart failure, with a focus on evaluating responses of the kidneys and the hormonal system.
What is the current status of trial NCT00620308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-06. Estimated completion is 2012-02.
What conditions does trial NCT00620308 study?
This clinical trial studies the following conditions: Stable Chronic Heart Failure.
What interventions are being tested in trial NCT00620308?
The interventions under investigation include: Placebo (DRUG), CD-NP (DRUG).
Who is sponsoring clinical trial NCT00620308?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00620308 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00620308's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia